CN105520129A - 一种番茄红素复方抗氧化保健食品 - Google Patents
一种番茄红素复方抗氧化保健食品 Download PDFInfo
- Publication number
- CN105520129A CN105520129A CN201510877149.2A CN201510877149A CN105520129A CN 105520129 A CN105520129 A CN 105520129A CN 201510877149 A CN201510877149 A CN 201510877149A CN 105520129 A CN105520129 A CN 105520129A
- Authority
- CN
- China
- Prior art keywords
- lycopene
- soybean
- extract
- tablet
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 title claims abstract description 46
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 title claims abstract description 46
- 239000001751 lycopene Substances 0.000 title claims abstract description 46
- 229960004999 lycopene Drugs 0.000 title claims abstract description 46
- 235000012661 lycopene Nutrition 0.000 title claims abstract description 46
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 title claims abstract description 46
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 21
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 19
- -1 Lycopene compound Chemical class 0.000 title claims description 13
- 235000013305 food Nutrition 0.000 title abstract description 5
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims abstract description 38
- 239000008601 oleoresin Substances 0.000 claims abstract description 26
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 235000020712 soy bean extract Nutrition 0.000 claims abstract description 4
- 235000010469 Glycine max Nutrition 0.000 claims description 25
- 244000068988 Glycine max Species 0.000 claims description 25
- 239000000284 extract Substances 0.000 claims description 24
- 235000006708 antioxidants Nutrition 0.000 claims description 15
- 239000003826 tablet Substances 0.000 claims description 14
- 235000013376 functional food Nutrition 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 7
- 235000013402 health food Nutrition 0.000 claims description 6
- 235000006539 genistein Nutrition 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 3
- 229940045109 genistein Drugs 0.000 claims description 3
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- 239000007910 chewable tablet Substances 0.000 claims description 2
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 239000007887 hard shell capsule Substances 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 abstract description 6
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 5
- 230000003712 anti-aging effect Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract 2
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 description 10
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- 230000000171 quenching effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000003405 preventing effect Effects 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940001593 sodium carbonate Drugs 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种抗氧化保健食品，该保健食品由以下重量份原料配比制成：番茄红素油树脂5～8份，大豆提取物1～3份。该发明将番茄红素油树脂与大豆提取物两种抗氧化物质按上述的配比结合，发挥其协同作用，抗氧化效果好，且同时能发挥两种物质的多种功效。本发明还进一步提供了上述保健食品在制备抗氧化、抗衰老产品中的应用。
Description
技术领域
本发明涉及保健食品的技术领域，具体是一种番茄红素复方抗氧化保健食品。
背景技术
中国保健食品行业兴起于上世纪80年代，短短十几年内，迅速发展成为一个独特的产业，特别是1998年至今，保健品行业进入了一个前所未有的高速发展时期。据统计，国外保健品在国内市场上的销量每年均以12%以上的速度在增长。保健食品主要包括食物补充剂（维生素、矿物质钙镁及微量元素、各种保健品）；含有生理活性物质的功能性饮料和食品；植物提取的天然色素和抗氧化剂；果蔬加工品；生物合成的功能低聚糖和多肽等。
氧化是肌肤衰老的最大威胁，饮食不健康、日晒、压力、环境污染等都能让肌肤自由基泛滥，从而产生面色黯淡、缺水等氧化现象，都是身体产生氧化的“罪魁祸首”。在正常情况下，人体内的自由基是处于不断产生与清除的动态平衡之中。自由基产生过多或清除过慢，它通过攻击生命大分子物质及各种细胞，会造成机体在分子水平、细胞水平及组织器官水平的各种损伤，加速机体的衰老进程并诱发各种疾病。人体在不可避免地产生自由基的同时，也在自然产生着抵抗自由基的抗氧化物质，以抵消自由基对人体细胞的氧化攻击。研究证明，人体的抗氧化***是一个可与免疫***相比拟的、具有完善和复杂的功能的***，机体抗氧化的能力越强，就越健康，生命也越长。机体的抗氧化作用，可保持自由基的产生与消除的平衡，对预防疾病与抗衰老等有重要意义。
目前尚没有采用大豆提取物与番茄红素油树脂组方制备的抗氧化功能的保健食品。
发明内容
本发明的目的在于提供一种番茄红素复方抗氧化保健食品，可增强抗氧化作用，同时兼有抗炎抗感染、缓解疲劳,增强免疫力等功效。
为实现上述目的，本发明公开了一种番茄红素复方抗氧化保健食品，由以下重量份原料配比制成：番茄红素油树脂5～8份，大豆提取物1～3份。
优选地，由以下重量份原料配比制成：番茄红素油树脂7份，大豆提取物2份。
其中，所述的番茄红素油树脂中番茄红素含量≥20%。
所述的大豆提取物中金雀异黄素含量≥8%。
本发明中的番茄红素油树脂和大豆提取物均可以通过直接购买市售品获得。
本发明保健食品的制备方法可以为：取所述重量份的番茄红素油树脂、大豆提取物，分别过筛，混匀，制粒，干燥，加入或不加辅料按照常规工艺制备成药剂学上任意一种剂型。
所述的剂型为颗粒剂或胶囊剂（硬胶囊、软胶囊）或片剂（普通片、分散片、口腔崩解片、含片、咀嚼片、泡腾片）或口服液体制剂等。
所述的辅料为：如在片剂、胶囊剂、颗粒剂等固体制剂中常用的稀释剂、崩解剂、赋形剂、粘合剂、润滑剂、填充剂等；在糖浆、口服液等口服液体制剂中常用的表面活性剂、稀释剂、防腐剂、稳定剂、矫味剂、增稠剂、助流剂等。具体是指淀粉、乳糖、糊精、糖粉、微晶纤维素、甘露醇、木糖醇、聚乙二醇、硫酸钙、磷酸氢钙、碳酸钙、改良淀粉、山梨醇、聚乙烯吡咯酮、重质碳酸镁、羧甲基纤维素钠、羟丙甲基纤维素、甲基纤维素、乙基纤维素、羧甲淀粉钠、羟丙基纤维素、聚维酮K30、白陶土、预胶化淀粉、硬脂酸镁、滑石粉、微粉硅胶、甜叶菊苷、甜菜碱、阿司帕坦、甘草甜素、糖精钠、枸橼酸、碳酸氢钠、碳酸钠、山梨酸钾、山梨酸等。
番茄红素通过物理和化学方式猝灭单线态氧或捕捉过氧化自由基。单线态氧是具有很强活性的氧自由基，具细胞毒性作用，以细胞膜、线粒体等部位对其最为敏感，能与细胞中多种生物大分子发生作用，通过与分子结合造成细胞膜***的损伤；番茄红素能够接受不同电子激发态的能量，吸收光能并通过单线态—单线态能量转移过程使单线态氧的能量转移到番茄红素，生成基态氧分子和三重态番茄红素分子，三重态番茄红素通过与溶剂的一系列旋光和振动反应得到再生，并在此过程中将能量散发；类胡萝卜素的猝灭能力与其分子中所含有的共轭双键的数目有着密切的关系，番茄红素分子中有11个共轭双键，一个番茄红素分子可以清除数千个单线态氧，其猝灭单线态氧的速率常数较大豆提取物高2倍。1990年Paolo等报道了类胡萝卜素和生育酚等30余种生物抗氧化剂猝灭单线态氧的作用，番茄红素是猝灭单线态氧最强的。
番茄红素还能通过与其他形式的活性氧的化学反应消除氧化自由基，如过氧化氢、亚硝酸根等氧化自由基，而氧化自由基能引起脂质过氧化形成多种产物，这些产物与人体老化、癌症发生、自身免疫病及贫血等疾病都有关系。
大豆提取中含有大量的金雀异黄素，其含5.7.4三个酚羟基，大豆甙元含7.4二个酚羟基。酚羟基作为供氧体能与自由基反应使之生成相应的离子或分子，熄灭自由基，终止了自由基的连锁反应。大豆异黄酮对整体动物也有比较明确的抗氧化作用，大豆异黄酮提取物对阿霉素引起的小鼠过氧化水平提高和抗氧化酶活性的降低也有明显的抑制作用。
动物与植物体内存在许多抗氧化物质参与组成体内的抗氧化剂，由于抗氧化物质众多，单个抗氧化剂对抗氧化状态功效并不能代表它们在体内相互协同作用。本发明将番茄红素油树脂与大豆提取物两种抗氧化物质按一定的配比结合，协同作用好，抗氧化效果好，且同时能发挥两种物质的多种功效，如眼和中枢神经***的保护作用、防紫外线辐射、抑制肿瘤、抗炎抗感染、缓解运动疲劳,增强机体能量代谢、增强免疫力、预防心血管疾病等。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白，以下结合实施例，对本发明进行进一步详细说明。
实施例采用的原料来源：大豆提取物（金雀异黄素含量≥8%），直接由市场购得，番茄红素油树脂（番茄红素含量≥20%），直接由市场购得。
实施例1
配制以下重量份原料：番茄红素油树脂5份，大豆提取物3份。制备方法如下：按配方比例称取过筛后的番茄红素油树脂及大豆提取物，共混均匀，制粒烘干，装入胶囊壳中得胶囊；或者用自动旋转扎囊机，压制法成型，得软胶囊；制备的辅料为常用辅料，每粒胶囊重约0.6g（其中番茄红素油树脂0.125g，大豆提取物0.075g）。用量为：每日服用两次，每次两粒，每日摄取的番茄红素油树脂0.5g，大豆提取物0.3g。
或者将上述原料加入到片剂成型机内挤压成型，得片剂。制备的辅料为常用辅料，每粒片剂重约0.5克（其中番茄红素油树脂0.17g，大豆提取物0.1g）。用量为：每日服用三次，每次一片，每日摄取的番茄红素油树脂0.5g，大豆提取物0.3g。
或者按上述配比直接用常规方法制备成口服制剂。
实施例2
配制以下重量份原料：番茄红素油树脂7份，大豆提取物2份。制备方法同实施例1。
每粒胶囊重约0.6g（其中番茄红素油树脂0.175g，大豆提取物0.05g）。用量为：每日服用两次，每次两粒，每日摄取的番茄红素油树脂0.7g，大豆提取物0.2g。
每粒片剂重约0.5克（其中番茄红素油树脂0.23g，大豆提取物0.07g）。用量为：每日服用三次，每次一片，每日摄取的番茄红素油树脂0.7g，大豆提取物0.2g。
抗氧化能力实验
在实验中，通过D-半乳糖注射建立的亚急性衰老小鼠模型后，使用本发明的抗氧化保健食品后，提高了小鼠机体SOD、GSH-Px抗氧化酶的活力,从而促进机体内自由基的消除，减轻脂质过氧化发生，保护生物膜，起到了抗氧化的作用，同时自由基的减少还能通过抑制细胞凋亡的机制延缓衰老，从实验结果可以看出，本发明配方的抗氧化保健食品的抗氧化能力要优于单一配方同等剂量的番茄红素油树脂及大豆提取物，说明番茄红素油树脂及大豆提取物经过该配比组合而成的配方发挥了二者的协同作用，具有更优质的效果。
以上所述，仅为本发明较佳的具体实施方式，但本发明的保护范围并不局限于此，任何熟悉本技术领域的技术人员在本发明揭露的技术范围内，可轻易想到的变化或替换，都应涵盖在本发明的保护范围之内。因此，本发明的保护范围应该以权利要求的保护范围为准。
Claims (3)
1.一种番茄红素复方抗氧化保健食品，其特征在于，由以下重量份原料配比制成：番茄红素油树脂5～8份，大豆提取物1～3份，，所述的番茄红素油树脂中番茄红素油含量≥20％，所述的大豆提取物中金雀异黄素含量≥8％。
2.如权利要求1所述的番茄红素复方抗氧化保健食品，其特征在于，由以下重量份原料配比制成：番茄红素油树脂7份，大豆提取物2份。
3.如权利要求1或2所述的番茄红素复方抗氧化保健食品，其特征在于，该保健食品被制备成胶囊剂或者片剂或者口服液体制剂，其中胶囊剂是指硬胶囊、软胶囊；片剂是指普通片、分散片、口腔崩解片、含片、咀嚼片、泡腾片。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510877149.2A CN105520129A (zh) | 2015-12-03 | 2015-12-03 | 一种番茄红素复方抗氧化保健食品 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510877149.2A CN105520129A (zh) | 2015-12-03 | 2015-12-03 | 一种番茄红素复方抗氧化保健食品 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105520129A true CN105520129A (zh) | 2016-04-27 |
Family
ID=55763040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510877149.2A Pending CN105520129A (zh) | 2015-12-03 | 2015-12-03 | 一种番茄红素复方抗氧化保健食品 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105520129A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105851816A (zh) * | 2016-05-13 | 2016-08-17 | 续智元 | 一种含有番茄红素馅的保健面食及其制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1736383A (zh) * | 2004-08-16 | 2006-02-22 | 新疆特丰药业股份有限公司 | 女用复方番茄红素制剂及其制备工艺 |
| CN103431401A (zh) * | 2013-09-16 | 2013-12-11 | 厦门中药厂有限公司 | 一种抗氧化保健食品及其应用 |
| CN104256579A (zh) * | 2014-05-05 | 2015-01-07 | 中粮屯河股份有限公司 | 一种基于番茄脂溶性提取物营养食品 |
| CN104643100A (zh) * | 2015-02-11 | 2015-05-27 | 浙江康恩贝集团医疗保健品有限公司 | 一种具有抗氧化功能的保健食品 |
-
2015
- 2015-12-03 CN CN201510877149.2A patent/CN105520129A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1736383A (zh) * | 2004-08-16 | 2006-02-22 | 新疆特丰药业股份有限公司 | 女用复方番茄红素制剂及其制备工艺 |
| CN103431401A (zh) * | 2013-09-16 | 2013-12-11 | 厦门中药厂有限公司 | 一种抗氧化保健食品及其应用 |
| CN104256579A (zh) * | 2014-05-05 | 2015-01-07 | 中粮屯河股份有限公司 | 一种基于番茄脂溶性提取物营养食品 |
| CN104643100A (zh) * | 2015-02-11 | 2015-05-27 | 浙江康恩贝集团医疗保健品有限公司 | 一种具有抗氧化功能的保健食品 |
Non-Patent Citations (3)
| Title |
|---|
| 云琦: "复方红素软胶囊的研制", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
| 刘丽等: "大豆异黄酮抗氧化作用的研究进展", 《中华放射医学与防护杂志》 * |
| 王秀玲等: "番茄红素油树脂的稳定性研究", 《天津科技大学学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105851816A (zh) * | 2016-05-13 | 2016-08-17 | 续智元 | 一种含有番茄红素馅的保健面食及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103431401B (zh) | 一种抗氧化保健食品及其应用 | |
| Lu et al. | Nutrients and bioactives in citrus fruits: Different citrus varieties, fruit parts, and growth stages | |
| Ciesarová et al. | Why is sea buckthorn (Hippophae rhamnoides L.) so exceptional? A review | |
| Wedamulla et al. | Citrus peel as a renewable bioresource: Transforming waste to food additives | |
| KR101661246B1 (ko) | 흡수 및 생물학적 이용 증진을 위한 완전 천연 종합 비타민 및 종합 미네랄 건강 보조제 | |
| Del Rı́o et al. | Citrus limon: A source of flavonoids of pharmaceutical interest | |
| EP0925068B1 (en) | Use of a pharmaceutical composition containing polyphenols from grapes or from wine, in particular resveratrol, and yeast extracts | |
| KR20200079202A (ko) | 고추씨 추출물을 함유하는 항산화 및 항염증용 조성물 | |
| CN102258196B (zh) | 一种具有抗氧化功能的保健食品 | |
| WO2013162484A1 (en) | A combination of fig (ficus carica) fruit extract and olive (olea europaea) leaf extract | |
| KR20160010884A (ko) | 항염증 활성이 우수한 섬쑥부쟁이 분획물 및 이로부터 분리된 활성화합물 | |
| CN105520129A (zh) | 一种番茄红素复方抗氧化保健食品 | |
| KR102554508B1 (ko) | 경구 미용제 | |
| JP2017178914A (ja) | 脳機能改善及び向上のための組成物 | |
| JP2007056219A (ja) | 抗酸化組成物 | |
| JP7445285B2 (ja) | カロテノイド含有食品 | |
| KR102590758B1 (ko) | 안토시아니딘 성분인 시아니딘, 델피니딘, 페튜니딘등을 함유한 빌베리 추출물의 항산화 또는 항염증용 조성물 | |
| Yaqoob et al. | Kinnow 21 | |
| Lee | Antioxidant Activity of Premature Mandarin (Citrus unshiu) and Its Effect on the Lipid Oxidation of Horse Oil-in-Water Emulsion | |
| Habeeb et al. | Vitamin C and Citrus peels—a treasure chest for healthy life | |
| AU2012200083B2 (en) | All natural multivitamin and multimineral dietary supplement formulations for enhanced absorption and biological utilization | |
| KR20150019676A (ko) | 항산화 및 피부 미백용 조성물 | |
| KR20230139411A (ko) | 시트러스 계열 과일 추출물을 유효성분으로 포함하는 항균용 조성물 | |
| JP6321908B2 (ja) | むくみ治療用経口組成物 | |
| KR20150057759A (ko) | 한방향 유효성분 리모넨(Ｌｉｍｏｎｅｎｅ)을 피부 유용성분으로 함유하는 화장료 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160427 |